Executive Vice President of Chiesi Global Rare Diseases. "As part of our mission to improve patient outcomes for the lysosomal disease community, we are committed to continual learning ...
no matter how rare their condition may be.” He continued: “Amryt has steadily brought innovative products to new markets and, by adding them to the Chiesi portfolio, we hope to make them ...
Italy’s Chiesi has created a new business unit aimed at increasing its presence in the market for rare disease drugs. Richard Staines spoke to Giacomo Chiesi, head of Chiesi Global Rare Diseases ...
Hosted on MSN2mon
EMA validates Chiesi and Protalix’s dose variation for Fabry diseaseThe European Medicines Agency (EMA) has validated Chiesi Global Rare Diseases and Protalix BioTherapeutics’ submission to update the dosing regimen of pegunigalsidase alfa, used in treating ...
About Chiesi Global Rare DiseasesChiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases.
PARMA, Italy, Feb. 3, 2025 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback